Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Research
Nature Biotechnology 25, 1159–1164 (1 October 2007) | doi:10.1038/nbt1332
Exploiting lymphatic transport and complement activation in nanoparticle vaccines
&
Abstract
Antigen targeting and adjuvancy schemes that respectively facilitate delivery of antigen to dendritic cells and elicit their activation have been explored in vaccine development. Here we investigate whether nanoparticles can be used as a vaccine platform by targeting lymph node–residing dendritic cells via interstitial flow and activating these cells by in situ complement activation.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
